The estimated Net Worth of Thomas J. Jr. Lynch is at least $574 ezer dollars as of 3 April 2019. Thomas Lynch owns over 11,594 units of Foghorn Therapeutics stock worth over $239,305 and over the last 15 years Thomas sold FHTX stock worth over $335,172.
Thomas has made over 5 trades of the Foghorn Therapeutics stock since 2017, according to the Form 4 filled with the SEC. Most recently Thomas exercised 11,594 units of FHTX stock worth $107,476 on 3 April 2019.
The largest trade Thomas's ever made was exercising 14,550 units of Foghorn Therapeutics stock on 14 May 2017 worth over $134,879. On average, Thomas trades about 1,380 units every 19 days since 2009. As of 3 April 2019 Thomas still owns at least 25,815 units of Foghorn Therapeutics stock.
You can see the complete history of Thomas Lynch stock trades at the bottom of the page.
Thomas's mailing address filed with the SEC is 500 TECHNOLOGY SQUARE, STE #700, CAMBRIDGE, MA, 02139.
Over the last 4 years, insiders at Foghorn Therapeutics have traded over $262,160 worth of Foghorn Therapeutics stock and bought 305,500 units worth $4,888,000 . The most active insiders traders include Adam Koppel, Ian F Smith és B Lynne Parshall. On average, Foghorn Therapeutics executives and independent directors trade stock every 109 days with the average trade being worth of $663,343. The most recent stock trade was executed by Steven F. Bellon on 9 September 2024, trading 20,000 units of FHTX stock currently worth $190,000.
Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines targeting genetically determined dependencies within the chromatin regulatory system. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system. It is developing FHD-286, a small molecule inhibitor of the enzymatic activity of BRG1 and BRM for the treatment of metastatic uveal melanoma and relapsed and/or refractory acute myeloid leukemia; and FHD-609, a small molecule protein degrader of BRD9 to treat patients with synovial sarcoma. The company is also developing an enzymatic inhibitor and a protein degrader as selective modulators of BRM; and ARID1B selective modulators for the treatment of ovarian, endometrial, colorectal, bladder, and gastric cancers. Foghorn Therapeutics Inc. has a research collaboration and license agreement with Merck Sharp & Dohme Corp. to discover and develop novel therapeutics based on disruptors of a specified transcription factor target. The company was founded in 2015 and is headquartered in Cambridge, Massachusetts.
Foghorn Therapeutics executives and other stock owners filed with the SEC include: